Skip to content

Thomas D. Meyer

4 papers in the library · 34 citations · publishing 2022-2025

Papers

Magic Mushrooms – an exploratory look at how mental health professionals feel and think about Psilocybin

Psychiatry Research July 16, 2022 Thomas D. Meyer, Priel Meir, Claudia Lex et al. 23 citations

Mental health professionals' attitudes toward psilocybin were neutral, but their self-rated knowledge of the substance was low. Whether the survey used the term 'Psilocybin' or 'Magic Mushrooms' did not significantly affect responses. Gender, attitudes toward medical cannabis, and personal history of psychedelic use were associated with ratings of psilocybin. These findings offer a baseline of mental health professionals' views on psilocybin, which may inform considerations if it receives FDA approval.

DOI: 10.1016/j.psychres.2022.114727 Psilocybin Hallucinogen Psychiatry Mental health +5

Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter?

Psychedelic Medicine August 18, 2023 Claudia Lex, Antonio F. Pagán, Jair C. Soares et al. 9 citations

Medical students hold generally positive attitudes toward psychedelic-assisted therapy, but their attitudes are significantly more favorable when the term "psilocybin" is used instead of "magic mushrooms." Personal experience with psychedelics is linked to more positive attitudes, beliefs, and higher self-rated knowledge. Attitudes and beliefs are stronger predictors of willingness to recommend psychedelic-assisted therapy, if FDA approved, than personal experience alone. The findings suggest that using the term "psilocybin" may be preferable in research and educational contexts.

DOI: 10.1089/psymed.2023.0022 Full text Psilocybin Psychology Terminology Transpersonal +1

Commentary on Methods for Addressing Functional Unblinding and Mechanistic Uncertainty in Clinical Trials of Psychedelic-Assisted Treatments

Current Treatment Options in Psychiatry November 11, 2025 Dan Petrovitch, Sarah E. Victor, A. Schmidt et al. 2 citations

The intense and distinctive subjective effects of psychedelics complicate tests of the efficacy and mechanisms of action of psychedelic-assisted treatments for mental-health conditions. Estimates of treatment efficacy are confounded under functional unblinding, and uncertainty surrounds whether subjective or neurobiological effects are causal mechanisms. Methodological solutions include improved active placebo conditions, expectancy-focused recruitment and consent procedures, better measurement of expectancies and blinding, and rigorous statistical modeling. Strategies to disentangle subjective and neurobiological effects include administering psychedelics under general anesthesia, developing non-psychoactive analogues, leveraging Mendelian randomization, and studying microdosing. Combining multiple innovative methods may offer the most robust insights.

DOI: 10.1007/s40501-025-00371-y Full text Clinical trial Placebo Medline Action physics +6